Radiotherapy Improves Survival in Early Stage Extranodal Natural Killer/T Cell Lymphoma Patients Receiving Asparaginase-based Chemotherapy

Overview

Journal Oncotarget

Specialty Oncology

Date 2016 Dec 22

PMID 28002792

Citations 7

Authors

Yi-Yang Li

Ling-Ling Feng

Shao-Qing Niu

Han-Yu Wang

Lu-Lu Zhang

Liang Wang

Zhong-Jun Xia

Hui-Qiang Huang

Yun-Fei Xia

Yu-Jing Zhang

Xi-Cheng Wang

Affiliations

Soon will be listed here.

Abstract

This study retrospectively investigated asparaginase-based chemotherapy treatment outcomes with or without radiotherapy in 143 patients with stage IE-IIE extranodal natural killer/T cell lymphoma (ENKTCL). All patients received a median of three cycles of asparaginase-based chemotherapy, while 121 patients received radiotherapy following the chemotherapy. The complete remission (CR) rate for all patients post-chemotherapy was 58.7%, and rose to 73.4% by the end of treatment. Patients who received radiotherapy achieved better survival outcomes than those who did not (89.7% vs. 49.0% for 2-year overall survival (OS), P<0.001; 86.8% vs. 37.4% for 2-year progression-free survival (PFS), P<0.001). Additionally, even patients who achieved CR post-chemotherapy exhibited differential survival rates with or without radiotherapy (90.8% vs. 60% for 2-year OS, P=0.006; 86.1% vs. 60% for 2-year PFS, P=0.044). Multivariate analysis revealed that radiotherapy was an independent factor favoring OS (HR=0.098, 95%CI=0.031-0.314, P=0.001) and PFS (HR=0.156, 95%CI=0.062-0.396, P=0.001). Thus, radiotherapy is recommended for stage IE-IIE ENKTCL patients treated with asparaginase-based chemotherapy, even in cases of CR following chemotherapy.

Citing Articles

A retrospective analysis of mature T- and NK-cell lymphomas.

Jia J, Wang X, Song Z, Meng S, Fei Y, Yu J Cancer Biol Med. 2024; 21(3).

PMID: 38544483 PMC: 10976325. DOI: 10.20892/j.issn.2095-3941.2023.0464.

Treatment of extranodal NK/T-cell lymphoma: From past to future.

Yan Z, Yao S, Wang Z, Zhou W, Yao Z, Liu Y Front Immunol. 2023; 14:1088685.

PMID: 36825002 PMC: 9941192. DOI: 10.3389/fimmu.2023.1088685.

Extranodal natural killer/T-cell lymphoma nasal type with extensive ocular tissue involvement: a case report.

Han R, Jiang Y, Bian A, Meng Z, Chen H, Ye J Diagn Pathol. 2021; 16(1):104.

PMID: 34763717 PMC: 8582105. DOI: 10.1186/s13000-021-01167-3.

What Effect Does Epstein-Barr Virus Have on Extranodal Natural Killer/T-Cell Lymphoma Prognosis? A Review of 153 Reported Cases.

Tvedten E, Richardson J, Motaparthi K Cureus. 2021; 13(9):e17987.

PMID: 34540511 PMC: 8445857. DOI: 10.7759/cureus.17987.

Radiotherapy followed by DICEP regimen in treatment of newly diagnosed, stage IE/IIE, extranodal NK/T-cell lymphoma patients.

Liu Y, Xue K, Xia Z, Jin J, Wang J, Sun H Cancer Med. 2020; 9(15):5400-5405.

PMID: 32519518 PMC: 7402823. DOI: 10.1002/cam4.3207.

References

Li Y, Liu Q, Fang H, Qi S, Wang H, Wang W . Variable clinical presentations of nasal and Waldeyer ring natural killer/T-cell lymphoma. Clin Cancer Res. 2009; 15(8):2905-12. DOI: 10.1158/1078-0432.CCR-08-2914. View

Huang H, Lin Z, Lin X, Cai Q, Xia Z, Jiang W . Long-term outcomes of patients with newly diagnosed extranodal natural killer/T-cell lymphoma treated by etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin regimen: a single-institution experience. Leuk Lymphoma. 2011; 52(6):1041-8. DOI: 10.3109/10428194.2011.561388. View

Kim W, Song S, Ahn Y, Ko Y, Baek C, Kim D . CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma?. Ann Oncol. 2001; 12(3):349-52. DOI: 10.1023/a:1011144911781. View

Tham I, Lee K, Yap S, Loong S . Outcome of patients with nasal natural killer (NK)/T-cell lymphoma treated with radiotherapy, with or without chemotherapy. Head Neck. 2005; 28(2):126-34. DOI: 10.1002/hed.20314. View

Harabuchi Y, Imai S, Wakashima J, Hirao M, KATAURA A, OSATO T . Nasal T-cell lymphoma causally associated with Epstein-Barr virus: clinicopathologic, phenotypic, and genotypic studies. Cancer. 1996; 77(10):2137-49. DOI: 10.1002/(SICI)1097-0142(19960515)77:10<2137::AID-CNCR27>3.0.CO;2-V. View

Cheson B, Pfistner B, Juweid M, Gascoyne R, Specht L, Horning S . Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25(5):579-86. DOI: 10.1200/JCO.2006.09.2403. View

Li Y, Yao B, Jin J, Wang W, Liu Y, Song Y . Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol. 2005; 24(1):181-9. DOI: 10.1200/JCO.2005.03.2573. View

Yamaguchi M, Kwong Y, Kim W, Maeda Y, Hashimoto C, Suh C . Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol. 2011; 29(33):4410-6. DOI: 10.1200/JCO.2011.35.6287. View

Zang J, Li C, Luo S, Wang J, Xu M, Zhao L . Early radiotherapy has an essential role for improving survival in patients with stage I-II nasal-type of NK/T cell lymphoma treated with L-asparaginase-containing chemotherapy--a single institution experience. Ann Hematol. 2014; 94(4):583-91. DOI: 10.1007/s00277-014-2244-4. View

10.

Yong W, Zheng W, Zhang Y, Zhu J, Wei Y, Zhu D . L-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma. Int J Hematol. 2003; 78(2):163-7. DOI: 10.1007/BF02983387. View

11.

Jaccard A, Gachard N, Marin B, Rogez S, Audrain M, Suarez F . Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood. 2010; 117(6):1834-9. DOI: 10.1182/blood-2010-09-307454. View

12.

Wang L, Wang W, Xia Z, Zhang Y, Xiang J, Lu Y . Combination of gemcitabine, L-asparaginase, and oxaliplatin (GELOX) is superior to EPOCH or CHOP in the treatment of patients with stage IE/IIE extranodal natural killer/T cell lymphoma: a retrospective study in a cohort of 227 patients with.... Med Oncol. 2014; 31(3):860. DOI: 10.1007/s12032-014-0860-4. View

13.

Zhou Z, Li X, Chen C, Li X, Zhang L, Li L . Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patients. Ann Hematol. 2014; 93(11):1889-94. DOI: 10.1007/s00277-014-2136-7. View

14.

Wang B, Lu J, Ma X, Guo Y, Lu H, Hong X . Combined chemotherapy and external beam radiation for stage IE and IIE natural killer T-cell lymphoma of nasal cavity. Leuk Lymphoma. 2007; 48(2):396-402. DOI: 10.1080/10428190601059795. View

15.

Niu S, Yang Y, Li Y, Wen G, Wang L, Li Z . Primary site and regional lymph node involvement are independent prognostic factors for early-stage extranodal nasal-type natural killer/T cell lymphoma. Chin J Cancer. 2016; 35:34. PMC: 4820898. DOI: 10.1186/s40880-016-0096-0. View

16.

Kim B, Kim T, Kim C, Kim J, Heo D, Bang Y . Therapeutic outcome of extranodal NK/T-cell lymphoma initially treated with chemotherapy--result of chemotherapy in NK/T-cell lymphoma. Acta Oncol. 2003; 42(7):779-83. DOI: 10.1080/02841860310010682. View

17.

Wang B, Li X, Ma X, Hong X, Lu H, Guo Y . Immunohistochemical expression and clinical significance of P-glycoprotein in previously untreated extranodal NK/T-cell lymphoma, nasal type. Am J Hematol. 2008; 83(10):795-9. DOI: 10.1002/ajh.21256. View

18.

Wang Z, Li Y, Wang W, Jin J, Wang H, Song Y . Primary radiotherapy showed favorable outcome in treating extranodal nasal-type NK/T-cell lymphoma in children and adolescents. Blood. 2009; 114(23):4771-6. DOI: 10.1182/blood-2009-07-235853. View

19.

Yong W, Zhang Y, Zheng W . [The efficacy of L-asparaginase in the treatment of refractory midline peripheral T-cell lymphoma]. Zhonghua Xue Ye Xue Za Zhi. 2001; 21(11):577-9. View

20.

Wang L, Wang Z, Chen X, Li Y, Wang K, Xia Y . First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma. Cancer. 2012; 119(2):348-55. DOI: 10.1002/cncr.27752. View